Head-To-Head Comparison: I-Mab (NASDAQ:NBP) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO)

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Valion Bio, Inc. Common Stock and I-Mab”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780,000.00	2.83	-$8.88 million	($159.25)	-0.02
I-Mab	$3.89 million	40.43	-$46.27 million	($0.36)	-3.78

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Valion Bio, Inc. Common Stock and I-Mab, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1	0	0	0	1.00
I-Mab	1	0	1	0	2.00

I-Mab has a consensus target price of $9.00, indicating a potential upside of 561.76%. Given I-Mab’s stronger consensus rating and higher possible upside, analysts plainly believe I-Mab is more favorable than Valion Bio, Inc. Common Stock.

Profitability

This table compares Valion Bio, Inc. Common Stock and I-Mab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
I-Mab	N/A	N/A	N/A

Volatility & Risk

Valion Bio, Inc. Common Stock has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Summary

I-Mab beats Valion Bio, Inc. Common Stock on 10 of the 13 factors compared between the two stocks.

About Valion Bio, Inc. Common Stock

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.